Market revenue in 2023 | USD 28.1 million |
Market revenue in 2030 | USD 69.9 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.14% in 2023. Horizon Databook has segmented the India head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India's head and neck cancer therapeutics market is driven by the increasing prevalence of head and neck cancer in the country, coupled with several awareness campaigns organized by governments to promote awareness regarding the condition.
According to an article published in the South Asian Journal of Cancer in January 2022, head and neck cancer accounted for about 30% of all cancer cases in India. According to the Foundation for Head and Neck Oncology (FHNO), in India, every year, over 200,000 cases of head and neck cancer occur in the country, of which about 40% are oral cancers.
The increasing prevalence of oral cancer in India can be attributed to high consumption of tobacco products, increasing alcohol consumption, increased prevalence of human papillomavirus (HPV) infection, and poor oral hygiene.
Horizon Databook provides a detailed overview of country-level data and insights on the India head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into India head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account